Stay tuned and follow the latest developments and news in Molecular Oncology.
This year, our team attended the San Antonio Breast Cancer Symposium (SABCS) in Texas, a key event in breast cancer research. It was a great opportunity to connect with healthcare professionals and learn about the latest advancements in the field.
At the symposium, two research abstracts involving Genekor’s scientific team were presented, showcasing valuable insights from Greek breast cancer cohorts:
Poster 1:
“PR status cannot predict Oncotype DX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX”
Presented by Prof. Vassilis Venizelos, MD, Breast Surgeon et al, the study demonstrated that PR status alone cannot predict the Recurrence Score (RS) or the benefit of chemotherapy.
Key finding: The Oncotype DX test plays a vital role in identifying patients with high RS (>25) who are most likely to benefit from chemotherapy, reinforcing the need for tailored treatment strategies.
Poster 2:
“The prognostic and predictive value of Oncotype DX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients”
Presented by Dr. Ioannis Natsiopoulos, MD, FEBS-BS et al, this study evaluated the prognostic and predictive utility of the Oncotype DX test in patients with ER+/HER2-/pT2N0, cM0 tumors.
Key finding: Among younger patients (≤50 years) with high clinical risk, 45.4% had a RS <16, suggesting they could avoid chemotherapy and benefit from endocrine therapy alone.
We are proud to have contributed to these important research efforts, supporting the use of genomic tools to guide personalized treatment approaches in breast cancer care.